Could an HIV drug fight fatal brain disease? new trial aims to find out
NCT ID NCT07482085
First seen Mar 26, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This phase 3 trial tests whether efavirenz, an HIV medication, can help people with Creutzfeldt-Jakob disease (CJD), a rare and fatal brain disorder. About 246 adults with CJD will receive either efavirenz or a placebo daily. The main goal is to see if the drug extends survival time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CREUTZFELDT-JAKOB DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, 100053, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.